MedTrace Logo

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

NCT03824535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-04-09

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Conditions

  • Cigarette Smoker
  • Current Smoker
  • Former Smoker
  • Multiple Pulmonary Nodules
  • Pulmonary Nodule

Interventions

DIAGNOSTIC_TEST

Computed Tomography

Undergo PET/CT

DRUG

Fludeoxyglucose F-18

Given IV

DRUG

Fluorine F 18 L-glutamate Derivative BAY94-9392

Given IV

DIAGNOSTIC_TEST

Positron Emission Tomography (PET/CT)

Undergo PET/CT

Sponsors & Collaborators

  • Canary Foundation

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Carina Mari Aparici · Stanford Cancer Institute Palo Alto

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2021-07-30
Completion
2021-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824535 on ClinicalTrials.gov